Transgene SA · EURONEXT:TNG
Transgene SA — Investor Presentation (August 2015)
26 slides from Transgene SA's investor presentation, Aug 26, 2015
Slide 1: Corporate Presentation August 26, 2015
Corporate Presentation August 26, 2015
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially fro
Slide 3: Transgene Highlights
TRANSGENE HIGHLIGHTS Discovering and Developing Targeted Immunotherapies to Treat Cancer and Infectious Diseases ● Immunotherapy approach complementary to other treatment types Viral vectors offer flexibility and adaptability based on indication and target Combine with traditional treatments suc
Slide 4: Company Snapshot
COMPANY SNAPSHOT Discovering and Developing Targeted Immunotherapies to Treat Cancer and Infectious Diseases ● Euronext: TNG ● Market cap: ~€ 150 million ● Shares outstanding: 38.5 million ● HQ in Strasbourg, France Office in Lyon, France Satellite offices in U.S. and China ● € 57 million in cas
Slide 5: Transgene – A Leader in Viral Vector-Based Immunotherapy
TRANSGENE – A LEADER IN VIRAL VECTOR-BASED IMMUNOTHERAPY Viral vector platforms – a method for delivering genetic material into cells… ..used by Transgene in multiple ways in oncology and infectious diseases Therapeutic Vaccines Therapeutic Payloads Targeted delivery of tumoral or Oncolytic Viruses
Slide 6: Diversified Development Pipeline
DIVERSIFIED DEVELOPMENT PIPELINE Internal Platforms have Delivered Multiple Programs Product Indications Pre-clinical ONCOLOGY TG4010 + chemotherapy in 1st line patients Non-small cell lung cancer (MVA-MUC1-IL2) + ICI Pexa-Vec (JX594/TG6006) Hepatocellular carcinoma 1st line patients (VV-TK-GM-CSF)
Slide 7: Active Immunotherapeutics and the Cancer-Immunity Cycle
ACTIVE IMMUNOTHERAPEUTICS AND THE CANCER-IMMUNITY CYCLE*: Strong Logic for Combination with ICIs Vaccines and oncolytics ICIs *Chen and Mellman – Immunity July 2013 ●●●●●●●●● 7
Slide 8: TG4010 Cancer Immunotherapy: Phase Ready in NSCLC
TG4010 CANCER IMMUNOTHERAPY: Phase 3 Ready in Non-small Cell Lung Cancer ● Target – MUC1 ● Lead indication – Non-small cell lung cancer (NSCLC) = large unmet medical need, large market opportunity Lung cancer accounts for more deaths than any other cancer type NSCLC global market expected to gro
Slide 9: TG4010: Phase 2b Part of Phase 2b/3 TIME Trial
TG4010: PHASE 2B PART OF PHASE 2B/3 TIME TRIAL Randomized, Double-blind, Multi-center Trial R normal A 222 Stage IV TrPAL N TG4010 (108 pfu)1 N Maintenance NSCLC patients (170) D + chemotherapy2 O therapy • PS 0,1 O N (pemetrexed or • MUC1+ M erlotinib or • No prior I P bevacizumab) + chemo high Z p
Slide 10: Promising Updated and New Data from TIME Trial Presented at ASCO 2015
TG4010 CANCER IMMUNOTHERAPY: Promising Updated and New Data from TIME Trial Presented at ASCO 2015 ● More mature data confirm strength of improvements in PFS and OS, especially in non-squamous tumors 88% of patients in TIME trial had non-squamous tumors Phase 3 - plan to enroll only patients wit
Slide 11: TG4010: Phase 2b TIME Trial Results
TG4010: PHASE 2B TIME TRIAL RESULTS ● Bayesian analysis to validate TrPAL biomarker Primary objective: PFS to prospectively validate the TrPAL predictive biomarker* o As recommended by the FDA, primary endpoint based on a Bayesian design: pooling PFS data from TIME Phase 2b trial and earlier study
Slide 12: Non-squamous: Statistically Significant PFS Results
TG4010: PHASE 2B TIME TRIAL RESULTS Non-squamous : Statistically Significant PFS Results Quoix, E. et al. Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy. ASCO Annual Meeting 2015 ●●
Slide 13: Non-squamous: Compelling OS Results
TG4010: PHASE 2B TIME TRIAL RESULTS Non-squamous : Compelling OS Results Quoix, E. et al. Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy. ASCO Annual Meeting 2015 ●●●●●●●●● 13
Slide 14: Non-squamous, Low TrPAL
TG4010: PHASE 2B TIME TRIAL RESULTS Non-squamous, Low TrPAL* Even greater improvements seen in non-squamous, low TrPAL group PFS OS PFS (months) OS (months) • The level of TrPAL cells at baseline as determined using a quartile approach; “low” TrPAL patients were in the three lowest quartiles. Quoix,
Slide 15: Activity in Patients with Low PD-L1 Expressing Tumors
TG4010: PHASE 2B TIME TRIAL RESULTS Activity of TG4010 in Patients with Low PD-L1 Expressing Tumors PFS OS PFS (months) OS (months) In a retrospective analysis, PD-L1 expression was analyzed in 160 patients by immunohistochemistry staining on tumor slides using the E1L3N anti-PD-L1 antibody. The cut
Slide 16: Response Rate and Duration of Response
TG4010: PHASE 2B TIME TRIAL RESULTS Response Rate and Duration of Response TG4010 Placebo Overall population (n) 111 111 ORR 39.6% 28.8% Median duration of response (wks) 30.1 18.7 Non-squamous (n) 98 98 ORR 39.8% 27.6% Median duration of response (wks) 40.9 18.1 Non-squamous, low TrPAL (n) 61 66 OR
Slide 17: TG4010 Phase 2b TIME Trial Conclusion
TG4010 TG4010: PHASE 2B TIME TRIAL RESULTS Conclusion ● TG4010 in combination with chemotherapy has demonstrated clinical efficacy Improved response rate and longer duration of response, including delayed and durable responses Significant improvement in PFS and improvement in overall survival ●
Slide 18: TG4010: Next Steps
TG4010: NEXT STEPS ● Initiate Phase 3 trial, subject to partnering Discussions with potential partners and with regulatory authorities ongoing ● Initiate exploratory Phase 2 trials in NSCLC in combination with ICIs Planning underway; potential collaborations with major cancer centers in France a
Slide 19: Pexa-Vec Oncolytic Immunotherapy for Liver and Other Cancers
PEXA-VEC ONCOLYTIC IMMUNOTHERAPY: Oncolytic Immunotherapy for Liver and Other Cancers ● Lead indication: hepatocellular carcinoma (HCC, liver cancer) Major unmet medical need with only one drug (sorafenib) approved for use Global HCC market expected to grow to over $950 million by 2018 ● SPA wit
Slide 20: Pexa-Vec: Key Clinical Results
PEXA-VEC: KEY CLINICAL RESULTS Clinical Activity Demonstrated in Several Trials ● More than 10 trials with >300 patients treated with Pexa-Vec in variety of tumor types, including liver, colorectal and kidney ● 30-patient dose-finding Phase 2 trial in HCC (80% of patients first- line) Proof of con
Slide 21: Pexa-Vec Oncolytic Immunotherapy Development Plan
PEXA-VEC ONCOLYTIC IMMUNOTHERAPY Development Plan ● Phase 3 trial in first-line HCC planned - SPA with FDA Pexa-Vec followed by sorafenib (Nexavar®) versus sorafenib alone Expected enrollment ~600 patients in Europe, North America and Asia 40% of costs borne by Transgene Orphan drug designat
Slide 22: TG1050 Adenovirus-Based HBV Immunotherapy
TG1050 ADENOVIRUS-BASED HBV IMMUNOTHERAPY Phase 1 Ready ● Large unmet medical need >240 million people have chronic liver infections; >780,000 deaths/yr due to consequences of hepatitis B Overall cure rate today = only ~3% of cases o Treatment duration = 15 years (in developed world), often for
Slide 23: Financials
FINANCIALS First Half 2015 Results to be Reported on September 10 At March 31, 2015: Balance sheet Cash and cash equivalents: € 57.0 million Cash burn for the 3 months ended March 31, 2015: Cash flow € 8.9 million ●●●●●●●●● 23
Slide 24: Ownership Structure
OWNERSHIP STRUCTURE 1 Retail investors 18% Institut Institut Mérieux Mérieux Institutional investors Institutional 52% investors Retail investors 30% 38.5 million shares outstanding + 1.4 million options and free shares2 1. As of March 14, 2014 2. As of Dec 31, 2014 ●●●●●●●●● 24
Slide 25: Potential Newsflow – Next Months
POTENTIAL NEWSFLOW – NEXT 12 MONTHS ● Business and financial update ● TG4010 Initiate further clinical development in NSCLC o Start Phase 3 part of TIME trial, subject to partnering o Initiate Phase 2 exploratory trial in combination with ICI Publish/present data from TIME trial ● Pexa-Vec Ini
Slide 26: Contact
CONTACT: Elisabetta Castelli, Director Investor Relations castelli@transgene.fr Laurie Doyle, Director Investor Relations U.S. & Corp Communications doyle@transgene.fr 400 Boulevard Gonthier d’Andernach - Parc d’Innovation - CS80166 - 67405 Illkirch Graffenstaden Cedex France Tél.: + 33 (0)3 88 27 9